Benzinga · Aug 31, 2026
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
GA
NASDAQ · GANX
Gain Therapeutics, Inc.
Healthcare · Biotechnology
$1.72
Up+$0.06 (+3.49%)
Updated Sep 17, 2026, 6:31 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 148.53M
- P/E ratio
- -6.72
- Dividend yield
- 0.00%
- 52-week range
- $1.53 – $3.07
- Volume
- 265.93K
- Avg. volume
- 1.01M
Price performance
GANX price history
1M range · 20 trading sessions · Daily adjusted prices
GANX closed at $1.72 after 20 trading sessions, down 16.91% for the selected period.
- Last close
- $1.72
- Period change
- -16.91%
- Period low
- $1.71
- Period high
- $2.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.73 | $1.7895 | $1.70 | $1.72 | 265.93K |
| Sep 15, 2026 | $1.74 | $1.74 | $1.69 | $1.71 | 215.69K |
| Sep 14, 2026 | $1.76 | $1.80 | $1.73 | $1.74 | 360.12K |
| Sep 11, 2026 | $1.748 | $1.78 | $1.72 | $1.75 | 223.56K |
| Sep 10, 2026 | $1.72 | $1.74 | $1.69 | $1.71 | 505.65K |
| Sep 9, 2026 | $1.81 | $1.83 | $1.72 | $1.72 | 513.39K |
| Sep 8, 2026 | $1.80 | $1.85 | $1.77 | $1.83 | 292.34K |
| Sep 4, 2026 | $1.81 | $1.83 | $1.785 | $1.80 | 205.35K |
| Sep 3, 2026 | $1.80 | $1.825 | $1.77 | $1.82 | 391.41K |
| Sep 2, 2026 | $1.78 | $1.846 | $1.75 | $1.79 | 367.69K |
| Sep 1, 2026 | $1.83 | $1.83 | $1.77 | $1.77 | 197.91K |
| Aug 31, 2026 | $1.77 | $1.84 | $1.76 | $1.80 | 259.89K |
| Aug 28, 2026 | $1.84 | $1.855 | $1.76 | $1.77 | 312.53K |
| Aug 27, 2026 | $1.85 | $1.90 | $1.795 | $1.85 | 416.11K |
| Aug 26, 2026 | $1.91 | $1.92 | $1.80 | $1.81 | 723.42K |
| Aug 25, 2026 | $2.00 | $2.05 | $1.90 | $1.905 | 383.52K |
| Aug 24, 2026 | $2.01 | $2.03 | $1.93 | $2.00 | 315.9K |
| Aug 21, 2026 | $2.00 | $2.045 | $1.98 | $2.005 | 277.48K |
| Aug 20, 2026 | $2.03 | $2.035 | $1.95 | $1.98 | 382.53K |
| Aug 19, 2026 | $2.02 | $2.085 | $2.02 | $2.07 | 300.04K |
Latest GANX news
The latest Smart Investors Daily articles mentioning GANX.
Stock researchCompany · Overview
GANX research
Overview
Company profile and research snapshot.
Company profile
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.50
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 1, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 30, 2026 | BTIG | Buy | — |
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share
Benzinga · Jul 16, 2026
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of
Benzinga · Jul 1, 2026
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
